Loading patent…
OwnerAlessandro Randazzoinventor
Estimating the term…
After refractive surgery to reduce ametropy (i.e. myopia, astigmatism or hypermetropia) an average percentage of patients between 15.8% after PRK (Photo Refractive Keratectomy) and 33% after LASIK (Laser in situ Keratomileusis) shows a poor night sight due to the presence of halos, glare and coma. A comparable disorder is present in a percentage of patients that underwent lensectomy (cataract or refractive lensectomy) with intra ocular lens (IOL) implant and IOL implants in phakic patients to reduce ametropy. Thanks to the effect on pupillary kinetics, diluted low concentrations (from 0.002% to 0.040%) of Aceclidine were surprisingly found to effectively reduce and/or eliminate night sight problems for about 6 hours.
Use of aceclidine or a pharmaceutically acceptable derivative thereof in the manufacture of a composition for the treatment of night sight problems (i.e. halos, coma and glare) in patients who underwent refractive surgery or intra ocular phakic lens implant or intra ocular implant in aphakic patients.
Pharmaceutical composition for the treatment of night sight problems (i.e. halos, coma and glare) in patients who underwent refractive surgery or intra ocular phakic lens implant or intra ocular implant in aphakic patients comprising aceclidine or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier.
Method to treat night sight problems (i.e. halos, coma and glare) in patients who underwent refractive surgery or intra ocular phakic lens implant or intra ocular implant in aphakic patients, which method comprises the topical administration of an effective amount of aceclidine in an ophthalmic composition to said patient in need of such treatment.
Dependencies are inferred from the claim text.